2nd Annual MarketsandMarkets Liquid Biopsy Virtual Conference

WHAT TO EXPECT

Identification of circulating biomarkers for early diagnosis
Incorporation of Artificial intelligence and machine learning in liquid biopsy
Challenges and advantages to the end users
Advancement in treatment and monitoring of cancer
Clinical and non-clinical application of liquid biopsy
Recent developments in assays for liquid biopsy

1)Hospitals/Universities/Labs: Hospitals - Diagnostics Department, Department of clinical oncology, Pathology Labs
-Designation - Oncologist, Immunologist, Hematologist, pathologist, General Practitioners, Lab managers, Lab directors, Medical directors
• Universities -Designation - Professors, Researchers, Associate professors in Cancer study
2) Pharma/Therapeutics: Designation - CEO, COO, Senior scientist in cancer and immunology, Research scientist in cancer, Personalized medicine individuals

Best networking opportunities with the industrial experts from all around the world
100+ experts attending
Interactive panel discussions with pioneers of the field
Platform to showcase/exhibit the innovative technologies
Expand on existing organizations and make new connections with across industry and the scholarly community

CONFERENCE AGENDA

Online Registration	08:30 - 09:00
Welcome note from MarketsandMarkets	08:55 - 09:00
Opening Remarks from the Chairman Emmanouil Karteris, Head of CBCEL, Brunel University London, UK	09:00 - 09:10
Presentation by: Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	12:05 - 12:35
EARLY DIAGNOSIS OF CANCER BY IDENTIFYING CIRCULATING BIOMARKERS
Keynote Presentation: Emerging technologies for interrogation of blood-based cancer biomarkers Emmanouil Karteris, Head of CBCEL, Brunel University London, UK	09:05 - 09:35
Urine - The Next Generation Early Disease Biomarker Source Youhe Gao, Professor Department of Biochemistry and Molecular Biology, Beijing Normal University	09:35 - 10:05
Liquid Biopsy John Yahya Elshimali, Associate Professor of Pathology, Charles Drew University and UCLA David Geffen School of Medicine	10:05 - 10:35
The FNIH Biomarkers Consortium ctDNA Quality Control Materials project and implementation of liquid biopsy standards through the International Liquid Biopsy Standardization Alliance (ILSA) Dana E. Connors, Senior Scientific Project Manager, Cancer Foundation for the National Institutes of Health	10:35 - 11:05
ctDNA for Early Assessment of Immunotherapy Response in Lung Cancer Patients. Azeet Narayan, Principal Scientist, Sema4 Holdings Corps, USA	11:05 - 11:35
Liquid Biopsy In Clinic and Clinical Research Dr. Harsha Doddihal, Clinical researcher, Oncologist, Fortis Hospital	11:35 - 12:05
Closing remarks from Chairman	12:35 - 12:40
End of Conference	12:40 - 12:40